Aker BioMarine AS provided revenue guidance for the full year of 2023. For the year, The company expects long-term average annual sales growth for Aker BioMarine to be in line with earlier communicated ambitions at around 15%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73 NOK | +1.39% | +3.99% | +58.70% |
04-26 | Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-26 | Transcript : Aker BioMarine AS, Q1 2024 Earnings Call, Apr 26, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+58.70% | 587M | |
+14.36% | 3.39B | |
-1.70% | 1.62B | |
-95.58% | 1.61B | |
-0.46% | 1.35B | |
-8.14% | 1.23B | |
-11.54% | 1.22B | |
-.--% | 1.21B | |
0.00% | 1.2B | |
+0.65% | 1.19B |
- Stock Market
- Equities
- AKBM Stock
- News Aker BioMarine
- Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023